192 related articles for article (PubMed ID: 24564402)
1. Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada.
Lachaine J; Beauchemin C; Mathurin K; Gilbert D; Beillat M
J Med Econ; 2014 Apr; 17(4):296-304. PubMed ID: 24564402
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada.
Lachaine J; Beauchemin C; Mathurin K; Gilbert D; Beillat M
BMC Psychiatry; 2014 Jan; 14():16. PubMed ID: 24450548
[TBL] [Abstract][Full Text] [Related]
3. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.
Sawyer L; Azorin JM; Chang S; Rinciog C; Guiraud-Diawara A; Marre C; Hansen K
J Med Econ; 2014 Jul; 17(7):508-19. PubMed ID: 24720805
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
6. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
Szegedi A; Verweij P; van Duijnhoven W; Mackle M; Cazorla P; Fennema H
J Clin Psychiatry; 2012 Dec; 73(12):1533-40. PubMed ID: 23290326
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context.
Caresano C; Di Sciascio G; Fagiolini A; Maina G; Perugi G; Ripellino C; Vampini C
Adv Ther; 2014 Aug; 31(8):873-90. PubMed ID: 25055791
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
[TBL] [Abstract][Full Text] [Related]
9. Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia.
McIntyre RS; Wong R
Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):217-20. PubMed ID: 22182459
[TBL] [Abstract][Full Text] [Related]
10. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
[TBL] [Abstract][Full Text] [Related]
11. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.
Landbloom R; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
CNS Spectr; 2017 Aug; 22(4):333-341. PubMed ID: 27821210
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis.
McIntyre RS; Cragin L; Sorensen S; Naci H; Baker T; Roussy JP
J Eval Clin Pract; 2010 Aug; 16(4):744-55. PubMed ID: 20545800
[TBL] [Abstract][Full Text] [Related]
13. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.
Edwards NC; Pesa J; Meletiche DM; Engelhart L; Thompson AK; Sherr J; Dirani R
Curr Med Res Opin; 2008 Dec; 24(12):3341-55. PubMed ID: 18954497
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.
Mahajan V; Arora M; Tandon VR; Gillani Z; Praharaj SK
J Clin Psychopharmacol; 2019; 39(4):305-311. PubMed ID: 31205195
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of olanzapine and risperidone in Norway.
Kim K; Aas E
J Ment Health Policy Econ; 2011 Sep; 14(3):125-35. PubMed ID: 22116170
[TBL] [Abstract][Full Text] [Related]
17. Asenapine: a clinical review of a second-generation antipsychotic.
Stoner SC; Pace HA
Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
[TBL] [Abstract][Full Text] [Related]
19. Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.
Schoemaker J; Naber D; Vrijland P; Panagides J; Emsley R
Pharmacopsychiatry; 2010 Jun; 43(4):138-46. PubMed ID: 20205074
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the clinical efficacy of asenapine in schizophrenia.
Minassian A; Young JW
Expert Opin Pharmacother; 2010 Aug; 11(12):2107-15. PubMed ID: 20642375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
